ERBB2 and breast carcinoma: Nonneville et al [8] in a multicenter retrospective cohort study examined the outcomes of subcentimeter, node-negative, HER2+ breast cancer and found a significantly higher DFS in patients who received adjuvant trastuzumab-based chemotherapy (HR 0.158 95% CI 0.045–0.